Amgen (AMGN) Swing
- Solid company
- Has had downward trend for weeks but is now at support
- For the six months ended 30 June 2021, Amgen, Inc. revenues increased less than 1% to 12.43B.
- Net income decreased 42% to 2.11B. Revenues reflect Prolia segment increase of 20% to 1.57B
- Other revenues segment increase of 28% to 721M, also reflect Enbrel segment decrease of14% to 2.07B, Neulasta segment decrease of 19% to 968M.
- Net income was partially offset by Research and development increase of 7% to 2.05B (expense), Selling.
- Has had downward trend for weeks but is now at support
- For the six months ended 30 June 2021, Amgen, Inc. revenues increased less than 1% to 12.43B.
- Net income decreased 42% to 2.11B. Revenues reflect Prolia segment increase of 20% to 1.57B
- Other revenues segment increase of 28% to 721M, also reflect Enbrel segment decrease of14% to 2.07B, Neulasta segment decrease of 19% to 968M.
- Net income was partially offset by Research and development increase of 7% to 2.05B (expense), Selling.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.